ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2019

Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…

Filed under:Drug Updates Tagged with:axial spondyloarthritis (SpA)Certolizumab PegolFDAnon-radiographic axial spondyloarthritisU.S. Food and Drug Administration (FDA)

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

Megan Brooks  |  April 25, 2019

NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:alendronatedenosumabFracturesOsteoporosisosteoporosis treatmentsosteoporotic fracture rates

FDA Approves New Osteoporosis Medication

Michele B. Kaufman, PharmD, BCGP  |  April 23, 2019

Romosozumab-aqqg has been approved in the U.S. for treating postmenopausal women with osteoporosis at high risk of fracture…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAOsteoporosisosteoporosis treatmentspostmenopausalpostmenopausal womenromosozumab-aqqgU.S. Food and Drug Administration (FDA)

Parent-Child Reminiscing Affects Children’s Pain Memories

Reuters Staff  |  April 22, 2019

NEW YORK (Reuters Health)—How parents and children reminisce about the child’s recent surgery affects the child’s pain memory, researchers from Canada report. Children who recall pain that is higher than initially reported are more likely to report more pain and distress during future pain experiences. These negatively biased memories, formed early in life, set the…

Filed under:Conditions Tagged with:juvenile surgerypain memoriesparent-child reminiscingpediatric pain management

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

Will Boggs MD  |  April 22, 2019

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…

Filed under:Biologics/DMARDsDrug Updates Tagged with:biosimilar CT-P13inflammatory bowel disease (IBD)infliximabinfliximab biosimilar

Advocacy Up Close: Dr. Gary Bryant Discusses the Role & Benefits of RheumPAC

Maura Iversen  |  April 18, 2019

RheumPAC, the ACR’s political action committee (PAC), is tasked with fundraising, vetting legislators, participating in Capitol Hill visits and developing important relationships for the College. During my interview with Gary Bryant, MD, the ACR’s inaugural RheumPAC chair, he shared his thoughts on the role of rheumatology advocacy in advancing clinical practice, research and education. ACR@Work: Have…

Filed under:Legislation & AdvocacyOpinionRheuminationsSpeak Out Rheum Tagged with:Gary Bryantpolitical action committee (PAC)rheumatology advocacyRheumPAC

Clusters of Autoimmune Liver Disease Suggest Environmental Trigger

Reuters Staff  |  April 17, 2019

NEW YORK (Reuters Health)—A large population-based study from the U.K. provides more evidence that some autoimmune liver diseases may be triggered by exposure to something in the environment. The study found a significant clustering of cases of primary biliary cholangitis (PBC), autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) in well-defined regions of north-east England…

Filed under:Conditions Tagged with:autoimmune hepatitisenvironmentenvironmental factorliverprimary sclerosing cholangitis

Why Fellows Should Care about ACR Advocacy

From the College  |  April 16, 2019

As a physician, I am an advocate. I am an advocate for my patients individually and collectively, and I am an advocate for my field: pediatric rheumatology. My own experiences as a patient drive me to integrate my patients’ perspectives into my medical decision making, and although my academic training has prepared me to best…

Filed under:From the CollegeLegislation & Advocacy Tagged with:RheumPAC

Dr. Brit Adler Treks Across Glaciers & Forages for Mushrooms

Carol Patton  |  April 16, 2019

In November 2017, Brit Adler, MD, an instructor in the Division of Rheumatology at Johns Hopkins University, Baltimore, was traveling across a glacier in the Cordillera Blanca mountain range in Peru. At nearly 15,000 feet high, the hikers in the caravan were secured to each other by ropes secured to harnesses. At that altitude, no…

Filed under:AudioProfilesRheum After 5 Tagged with:Dr. Brit Adler

Ethics Forum: Patient Safety at Home—What Are Our Legal & Ethical Responsibilities?

Sarah F. Keller, MD, & Marcy B. Bolster, MD  |  April 15, 2019

A 60-year-old woman with a six-month history of retroperitoneal fibrosis transfers her care to you. She initially presented with severe bilateral flank pain radiating to the abdomen and chest. A computerized tomography (CT) angiogram of the abdomen demonstrated an infrarenal abdominal aortic aneurysm surrounded by a thick inflammatory rind entangling the left renal vein and…

Filed under:EthicsLegal Updates Tagged with:abuseEthics Forumpatient safetyreporting

  • « Previous Page
  • 1
  • …
  • 132
  • 133
  • 134
  • 135
  • 136
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences